Anlon Healthcare IPO
Open MainLineCurrent GMP
₹1 (+1.10%)
Price Band
₹ 86 – 91
Lot Size
164
Issue Size
₹121.03 Cr
Minimum Investment
₹14924 (164 Shares)
Listing Date
03 September 2025
Subscription
7.13x
About the Company
Incorporated in 2013, Anlon Healthcare Limited is a specialty chemical manufacturing company focused on the production of high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs). These products are critical components used in the formulation of medicines, nutraceuticals, personal care items, and veterinary products.
Core Capabilities
Anlon manufactures pharmaceutical intermediates and APIs in compliance with global pharmacopeia standards, including IP, BP, EP, JP, and USP. The company has also expanded into custom synthesis of complex chemicals, offering solutions that exceed purity requirements and meet stringent customer specifications.
The company's API portfolio includes products approved by major regulatory bodies such as:
- ANVISA (Brazil)
- NMPA (China)
- PMDA (Japan)
Notably, Anlon is among the few Indian manufacturers of Loxoprofen Sodium Dihydrate, a widely used anti-inflammatory API.
Product Portfolio (As of January 31, 2025)
Anlon’s portfolio spans 142 products across various stages of development:
- 65 Commercialized
- 28 At pilot stage
- 49 In laboratory testing
Breakdown by category:
- 22 Pharmaceutical Intermediates
- 18 Active Pharmaceutical Ingredients (APIs)
- 20 Nutraceutical APIs
- 3 Personal Care Intermediates
- 2 Veterinary APIs
The company has filed 21 Drug Master Files (DMFs) across global jurisdictions and is actively pursuing additional filings, including for Ketoprofen and Dexketoprofen Trometamol.
Manufacturing and Quality
With a strong focus on quality, safety, and environmental responsibility, Anlon ensures all products undergo rigorous testing, analysis, and process validation. Supported by four in-house laboratories, the company's quality systems are managed by a 34-member team—including 24 science graduates—dedicated to R&D, QC, and QA.
Workforce
As of January 31, 2025, Anlon employed:
- 105 full-time employees (excluding trainees)
- 8 contract workers
Key Products
- Pharma Intermediates: Examples include Cyanoethylbenzoic Acid, Ketonitrile, and Methyldesloratadine, used as starting materials or advanced intermediates in API manufacturing.
- Active Pharmaceutical Ingredients (APIs): Used in tablets, capsules, syrups, ointments, and other formulations across human and animal health, nutraceuticals, and personal care.
Global Reach
Anlon serves clients in over 15 countries, including Italy, Germany, Japan, and Brazil.
Competitive Strengths
- Diverse and scalable product portfolio
- Strong promoter backing and experienced management
- High entry barriers due to long customer approval cycles
- In-house capabilities for testing, quality control, and assurance
- Commitment to quality, environment, health, and safety standards
Promoters
- Punitkumar R. rasadia
- Meet Atulkumar Vachhani
- Mamata punitkumar Rasadia
Promoters Holding
Holding Pre Issue
70.26%
Holding Post Issue
52.68%
Objects of the Issue
The Company Anlon Healthcare IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
- Funding capital expenditure requirements for Proposed Expansion
- Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company
- Funding the working capital requirements of the Company
- General corporate purposes
Address / Contact Info
Anlon Healthcare Limited
101/102, Silvercoin Complex,
Opp.Crystal Mall,
Kalawad Road,
Rajkot, Gujarat, 360005
Phone: +91 281 2562538
Email: cs@anloncro.com
Website: http://www.anlon.in/
IPO Snapshot
IPO Timeline (Tentative)
IPO Open Date
Tuesday, 26 August 2025
IPO Close Date
Friday, 29 August 2025
Basis of Allotment
Monday, 01 September 2025
Initiation of Refunds
Tuesday, 02 September 2025
Credit of Shares to Demat
Tuesday, 02 September 2025
Listing Date
Wednesday, 03 September 2025 — NSE & BSE
Important Dates
Open Date
26 August 2025
Close Date
29 August 2025
Basis Of Allotment
01 September 2025
Listing Date
03 September 2025
Financial Performance (₹ in Crores)
| Particular | 31 Jan 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 181.3 | 128 | 111.55 |
| Revenue | 120.46 | 66.69 | 113.12 |
| Profit After Tax | 20.52 | 9.66 | 5.82 |
| Net Worth | 80.42 | 21.03 | 7.37 |
| Reserve & Surplus | 40.57 | 5.03 | -4.63 |
| Total Borrowings | 58.35 | 74.56 | 66.39 |
EPS Pre
5.15%
EPS Post
3.86%
P/E Pre
17.67
P/E (Post Issue)
23.57x
Company Financial Information
KPI Information (₹ in Crores)
| Particular | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE % | 40.45 | 67.99 | 130.37 |
| ROCE % | 21.93 | 16.29 | 17.16 |
| Debt / Equity | 0.73 | 3.55 | 9 |
| RoNW % | 25.21 | 45.92 | 78.92 |
| PbW | 0 | 0 | 0 |
| Pat Margin % | 17.06 | 14.5 | 5.16 |
Return Ratio
IPO Reservations
| Category | Shares Offered | Shares Offered % | Max Allotee |
|---|---|---|---|
| Qualified Institutions | 9975000 | 75 | 0 |
| Non-Institutional | 1995000 | 15 | 0 |
| BNII | 1330000 | 10 | 0 |
| SNII | 665000 | 5 | 0 |
| Retail Investors | 1330000 | 10 | 0 |
| Total | 13300000 | 100 | 0 |
Subscription Status ( Fri, 29 Aug 25 01:45 PM)
| Category | Shares Offered | Shares Bid For | Subscription (x) |
|---|---|---|---|
| Qualified Institutions | 9975000 | 10689028 | 1.07x |
| Non-Institutional | 1995000 | 21161412 | 10.61x |
| BNII | 1330000 | 10059924 | 7.56x |
| SNII | 665000 | 11101488 | 16.69x |
| Retail Investors | 1330000 | 62912368 | 47.3x |
| Total | 13300000 | 94762808 | 7.13x |
Subscription figures are updated periodically and may change until issue closing. Data reflects bids placed across exchanges.
Peer Comparision
| Company | Face Value | PE Ratio | EPS Basic | EPS Diluted | RoNW | Net Assets |
|---|---|---|---|---|---|---|
| Anlon Healthcare Ltd | 10 | 0.00 | 6.38 | 6.38 | 25.51 | 20.18 |
| Kronox Lab Sciences Ltd | 10 | 26.18 | 6.91 | 6.91 | 28.26 | 24.28 |
| Acutaas Chemicals Ltd | 5 | 58.47 | 19.81 | 19.81 | 12.15 | 161.24 |
| Supriya Lifeciences Ltd | 2 | 29.27 | 23.35 | 23.35 | 18.86 | 123.85 |
Lot Size & Investment Details
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 164 | 14,924.00 |
| Retail (Max) | 13 | 2,132 | 194,012.00 |
| S-HNI (Min) | 14 | 2,296 | 208,936.00 |
| S-HNI (Max) | 67 | 10,988 | 999,908.00 |
| B-HNI (Min) | 68 | 11,152 | 1,014,832.00 |
Registrar
Kfin Technologies Limited
04067162222, 04079611000
reachus@kfintech.com
https://www.kfintech.com
Book Running Lead Managers
- Interactive Financial Services Ltd
RHP Document
DRHP Document
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Anlon Healthcare IPO is a Book-building IPO worth ₹121.03 crores. The price band is ₹86 to 91 per share. The IPO opens on Tue, Aug 26, 2025 and closes on Fri, Aug 29, 2025. It will be listed on BSE and NSE. Kfin Technologies Limited is the registrar.
The Anlon Healthcare IPO opens on Tue, Aug 26, 2025 and closes on Fri, Aug 29, 2025
Anlon Healthcare IPO Price Band is ₹86 to 91.
Anlon Healthcare IPO lot size is 164, and the minimum amount required for application is ₹14924.
The minimum investment for Anlon Healthcare IPO is approximately ₹14924 based on the upper price band.
To apply for the Anlon Healthcare IPO, investors can use the ASBA (Application Supported by Blocked Amount) process via their bank's net banking or apply through UPI using a registered broker or trading app. The IPO is available in retail, HNI, and institutional investor categories. Investors must select the lot size, enter bid details within the price band, and submit their application before the IPO closing date of Fri, Aug 29, 2025. After submission, funds are blocked until the basis of allotment of Anlon Healthcare IPO is finalised.
Anlon Healthcare IPO issue size is ₹121.03 crores.
Anlon Healthcare IPO allotment date is Sat, Jun 27, 2026.
The registrar for Anlon Healthcare IPO is Kfin Technologies Limited. Investors can go to Kfin Technologies Limited website for IPO allotment status, refund processing, and other queries related to Anlon Healthcare IPO through their official website or helpline.
The Anlon Healthcare IPO GMP (Grey Market Premium) is ₹1 as of Wed, Sep 3, 2025. Based on the upper price band of ₹91 per share, the estimated Anlon Healthcare IPO listing price is ₹92, indicating a potential listing gain of approximately 31% over the issue price.